Outcomes of Pulmonary Artery Denervation for Treatment of PAH
Presenter:
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Elucid Bio; Heartflow; Abiomed; Valfix; Therox; Gore; Ablative Solutions; Miracor Medical SA; Ancora; Vectorious; Robocath; Neovasc; Cardiomech
- Equity/Stock(s)/Options (Personal) - SpectraWave; Orchestra Biomed; Applied Therapeutics; Biostar Family of Funds; Aria; Cardiac Success; Valfix; Ancora; Cagent
- Grant Support/Research Contract (Institutional) - Phillips; Vascular Dynamics; V-Wave; Biosense Webster; Abbott Vascular; Bioventrix; CSi